Cabaletta Bio (CABA) Income from Continuing Operations (2018 - 2026)
Cabaletta Bio (CABA) posted quarterly Income from Continuing Operations of 48509000.0 for Q4 2025, down 48.2% year-over-year from 93647690.24 in Q4 2024, and up 27.53% quarter-over-quarter from 66934000.0 in Q3 2025.
Cabaletta Bio (CABA) Income from Continuing Operations (2018 - 2026) Analysis & Trends
Cabaletta Bio's Income from Continuing Operations history runs 8 years deep, the most recent figure standing at 48509000.0 for Q4 2025.
- In Q4 2025, Income from Continuing Operations fell 48.2% year-over-year to 48509000.0; the TTM figure through Dec 2025 stood at 205634000.0 (up 4.1% YoY), while the FY2025 annual figure was 324060000.0, down 43.49% from the prior year.
- Income from Continuing Operations for Q4 2025 stood at 48509000.0, up from 66934000.0 in the prior quarter.
- The five-year high for Income from Continuing Operations was 13890367.0 in Q4 2021, with the low at 94812000.0 in Q1 2024.
- The 5-year median for Income from Continuing Operations is 33411500.0 (2023), against an average of 38587268.35.
- The sharpest annual moves came in 2023 and 2025: Income from Continuing Operations sank 327.09% in 2023, then soared 56.62% in 2025.
- Cabaletta Bio's Income from Continuing Operations stood at 13890367.0 in 2021, then slumped by 33.92% to 18602000.0 in 2022, then decreased by 3.09% to 19177000.0 in 2023, then sank by 70.68% to 32732000.0 in 2024, then slumped by 48.2% to 48509000.0 in 2025.
- Business Quant data shows CABA's Income from Continuing Operations at 48509000.0 in Q4 2025, 66934000.0 in Q3 2025, and 49062000.0 in Q2 2025.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Income (Continuing) (Qtr) |
|---|---|---|---|---|---|
| 1 | Vertex Pharmaceuticals | 128.13 Bn | 120.28 Bn | 2.84 Bn | 1.10 Bn |
| 2 | Regeneron Pharmaceuticals | 112.33 Bn | 104.33 Bn | 3.93 Bn | 1.30 Bn |
| 3 | Argenx Se | 53.24 Bn | 48.05 Bn | 1.41 Bn | 482.00 Mn |
| 4 | Revolution Medicines | 43.64 Bn | 43.64 Bn | - | -644.37 Mn |
| 5 | BeOne Medicines | 39.27 Bn | 34.17 Bn | 1.53 Bn | 237.01 Mn |
| 6 | MindWalk Holdings | 35.32 Bn | 35.31 Bn | 1.82 Bn | -3,096.02 |
| 7 | Royalty Pharma | 33.72 Bn | 35.84 Bn | - | 81.49 Mn |
| 8 | Alnylam Pharmaceuticals | 30.58 Bn | 27.27 Bn | 992.69 Mn | 164.49 Mn |
| 9 | Insmed | 27.01 Bn | 25.85 Bn | 358.27 Mn | -13.27 Mn |
| 10 | Cabaletta Bio | 466.25 Mn | 466.25 Mn | - | -70.39 Mn |
Historic Data
Download Data| Date | Value |
|---|---|
| Jun 30, 2026 | -70.39 Mn |
| Dec 31, 2025 | -48.51 Mn |
| Sep 30, 2025 | -66.93 Mn |
| Jun 30, 2025 | -49.06 Mn |
| Mar 31, 2025 | -41.13 Mn |
| Dec 31, 2024 | -32.73 Mn |
| Sep 30, 2024 | -45.85 Mn |
| Jun 30, 2024 | -41.03 Mn |
| Mar 31, 2024 | -94.81 Mn |
| Dec 31, 2023 | -19.18 Mn |
| Sep 30, 2023 | -75.33 Mn |
| Jun 30, 2023 | -56.42 Mn |
| Mar 31, 2023 | -34.09 Mn |
| Dec 31, 2022 | -18.60 Mn |
| Sep 30, 2022 | -17.64 Mn |
| Jun 30, 2022 | -22.66 Mn |
| Mar 31, 2022 | -23.46 Mn |
| Dec 31, 2021 | -13.89 Mn |
| Sep 30, 2021 | -28.04 Mn |
| Jun 30, 2021 | -19.56 Mn |